Fmr LLC Boosts Stock Holdings in STAAR Surgical (NASDAQ:STAA)

Fmr LLC lifted its stake in STAAR Surgical (NASDAQ:STAA) by 79.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,092 shares of the medical instruments supplier’s stock after purchasing an additional 3,136 shares during the period. Fmr LLC’s holdings in STAAR Surgical were worth $263,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Arcadia Investment Management Corp MI purchased a new position in shares of STAAR Surgical in the 3rd quarter valued at about $37,000. Quest Partners LLC purchased a new position in STAAR Surgical in the third quarter worth approximately $128,000. Canada Pension Plan Investment Board acquired a new position in STAAR Surgical during the 2nd quarter worth approximately $129,000. Van ECK Associates Corp increased its position in shares of STAAR Surgical by 12.7% in the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock valued at $129,000 after purchasing an additional 393 shares during the last quarter. Finally, Larson Financial Group LLC acquired a new stake in shares of STAAR Surgical in the 2nd quarter valued at $130,000. 96.70% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at STAAR Surgical

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 23,000 shares of the stock in a transaction on Wednesday, December 18th. The shares were bought at an average cost of $24.33 per share, with a total value of $559,590.00. Following the transaction, the insider now owns 10,848,631 shares of the company’s stock, valued at approximately $263,947,192.23. This trade represents a 0.21 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on STAA shares. Stifel Nicolaus lowered their target price on shares of STAAR Surgical from $50.00 to $44.00 and set a “buy” rating for the company in a research note on Monday, August 26th. Stephens raised STAAR Surgical to a “hold” rating in a research report on Monday, December 2nd. Canaccord Genuity Group dropped their price objective on STAAR Surgical from $31.00 to $28.00 and set a “hold” rating on the stock in a report on Monday, December 9th. Finally, Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, STAAR Surgical has an average rating of “Hold” and an average target price of $42.83.

STAAR Surgical Stock Performance

STAA opened at $24.82 on Friday. STAAR Surgical has a one year low of $23.72 and a one year high of $52.68. The stock has a market capitalization of $1.22 billion, a P/E ratio of 56.41 and a beta of 0.59. The business’s 50-day simple moving average is $28.31 and its 200-day simple moving average is $34.56.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.